Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781359 | 0.79 | RXFP1 (0.40) | RXFP1ALDH1A1GPR84KDM4ESMYD3 | |
| SCHEMBL4395036 | 0.76 | SMYD3 (0.44) | POLBALDH1A1RAB9AMAPTKDM4E | |
| SCHEMBL6766391 | 0.75 | KDM4E (0.59) | RXFP1SMN1; SMN2POLBALDH1A1NPC1 | |
| SCHEMBL22425114 | 0.73 | ALDH1A1 (0.76) | SMN1; SMN2ALDH1A1HTTMAPTKDM4E | |
| SCHEMBL7361096 | 0.72 | SMN1; SMN2 (0.41) | SMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL11296648 | 0.72 | HDAC3 (0.45) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL12658568 | 0.72 | PRSS1 (0.43) | SMN1; SMN2HTTRAB9AMAPT | |
| SCHEMBL6767250 | 0.72 | RAB9A (0.64) | RXFP1POLBALDH1A1HTTNPC1 | |
| SCHEMBL12658567 | 0.70 | HCAR3 (0.53) | SMN1; SMN2POLBALDH1A1HTTMAPT | |
| SCHEMBL6763737 | 0.70 | MAPT (0.50) | RXFP1SMN1; SMN2POLBALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | claimed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | claimed |
| US-20060154977-A1 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD, CORPORATION | 2006-07-13 | — | — | US | claimed |
| EP-1511736-A4 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2006-06-07 | — | — | EP | claimed |
| EP-1511736-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | Cortical Pty Ltd (AU) | 2005-03-09 | — | — | EP | claimed |
| WO-2003104203-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2003-12-18 | — | — | WO | claimed |
| EP-2319838-A1 | Therapeutic Molecules and Methods-1 | Cortical Pty Ltd (AU) | 2011-05-11 | — | — | EP | disclosed |
| EP-2319838-A1 | Therapeutic Molecules and Methods-1 | Cortical Pty Ltd (AU) | 2011-05-11 | — | — | EP | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-20060154977-A1 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD, CORPORATION | 2006-07-13 | — | — | US | disclosed |
| EP-1511736-A4 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2006-06-07 | — | — | EP | disclosed |
| EP-1511736-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | Cortical Pty Ltd (AU) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003104203-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154977-A1 | Therapeutic molecules and methods-1 | MIF, IL1B, IL1A | RXFP1 589/4885SMN1; SMN2 3844/4885POLB 3151/4885 |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MIF, IL1B, IL1A | RXFP1 589/4885SMN1; SMN2 3844/4885POLB 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.